Pneumologie, Table of Contents Pneumologie 2024; 78(03): 143-144DOI: 10.1055/a-2204-5542 Pneumo-Fokus Kommentar Authors Contributor(s): Tobias Notz Recommend Article Abstract Buy Article(opens in new window) Comment on:Osimertinib verbessert bei EGFR-mutiertem NSCLC auch das GesamtüberlebenPneumologie 2024; 78(03): 143-143DOI: 10.1055/a-2196-8365 Full Text References Literatur 1 Wu Y-L. et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology 2021; 17: 423-433 2 Herbst RS. et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023; 41: 1830-1840
